1351522-04-7

Basic information

• Product Name: AC710
• Synonyms: AC710;N-[4-[[[[5-(1,1-Dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenyl]-5-[(1-ethyl-2,2,6,6-tetramethyl-4-piperidinyl)oxy]-2-pyridinecarboxamide;5-[(1-Ethyl-2,2,6,6-tetramethyl-4-piperidinyl)oxy]-N-[4-({[5-(2-methyl-2-propanyl)-1,2-oxazol-3-yl]carbamoyl}amino)phenyl]-2-pyridinecarboxamide
• CAS NO: 1351522-04-7
• Molecular Formula: C₃₁H₄₂N₆O₄
• Molecular Weight: 562.70298
• Mol File: 1351522-04-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 580.4±50.0 °C(Predicted)
• Appearance: /
• Density: 1.180±0.06 g/cm3(Predicted)
• PKA: 10.91±0.70(Predicted)
• CAS DataBase Reference: AC710(CAS DataBase Reference)
• NIST Chemistry Reference: AC710(1351522-04-7)
• EPA Substance Registry System: AC710(1351522-04-7)

Safety Data

• Hazardous Substances Data: 1351522-04-7(Hazardous Substances Data)

Usage

Uses

AC 710 is a globally selective inhibitor of platelet-derived growth factor receptor-family kinases and has been shown to have potential anti-arthritic theapeutic use.

Upstream product

• 106590-40-3 1-ethyl-2,2,6,6-tetramethylpiperidin-4-ol 
• 852668-37-2 1-(4-aminophenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea 
• 1351503-95-1 5-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yloxy)picolinic acid 
• 327056-62-2 5-fluoropicolinonitrile 

Downstream Products

• 1351522-05-8 N-(4-(3-(5-tert-butylisoxazol-3-yl)ureido)phenyl)-5-(1-ethyl-2,2,6,6-tetramethylpiperidin-4-yloxy)picolinamide methanesulfonate salt 

Relevant articles and documents

Discovery of AC710, a globally selective inhibitor of platelet-derived growth factor receptor-family kinases

A series of potent, selective platelet-derived growth factor receptor-family kinase inhibitors was optimized starting from a globally selective lead molecule 4 through structural modifications aimed at improving the physiochemical and pharmacokinetic properties, as exemplified by 18b. Further clearance reduction via per-methylation of the α-carbons of a solubilizing piperidine nitrogen resulted in advanced leads 22a and 22b. Results from a mouse tumor xenograft, a collagen-induced arthritis model, and a 7 day rat in vivo tolerability study culminated in the selection of compound 22b (AC710) as a preclinical development candidate.